Litigation

Recent Posts

Generic Drug Failure-To-Update Preemption Ruling Won’t Be Reviewed By High Court
Posted on 20 Jan 2015 by Tom Moylan

WASHINGTON, D.C. — (Mealey’s) The U.S. Supreme Court on Jan. 20 denied review of a California appeals court ruling that a drug company may be liable for failure to update a generic drug’s warning label ( Teva Pharmaceuticals USA Inc... Read More

Tags: drugs , preemption , Barr Pharmaceuticals LLC , California , U.S. Food Drug and Cosmetic Act , product liability , Buckman Co. v. Plaintiffs’ Legal Comm. , FDA , Caraco Pharmaceutical Laboratories Ltd. , PLIVA Inc. v. Mensing , Teva Pharmaceuticals USA Inc. v. Superior Court of California , Litigation , PLIVA Inc. v. Theresa Huck , Teva Pharmaceuticals USA Inc. , generic drug , U.S. Supreme Court , torts

Supreme Court Questions If New Hampshire Law Escapes Preemption Of Drug Claims
Posted on 20 Mar 2013 by Tom Moylan

WASHINGTON, D.C. - (Mealey's) Several U.S. Supreme Court justices on March 19 questioned whether New Hampshire law allows a design defect claim against a generic drug manufacturer that escapes preemption under the high court's two drug preemption... Read More

Tags: Clinoril , preemption , design defect , toxic epidermal necrolysis , Stevens-Johnson syndrome , Mutual Pharmaceutical Company , PLIVA Inc. v. Mensing , Inc. v. Karen L. Bartlett , Litigation , generic drug , New Hampshire law , U.S. Supreme Court , sulindac , Mutual Pharmaceutical Co. , Karen L. Bartlett , Wyeth v. Levine

U.S. Supreme Court Will Rule On Preemption Of Generic Drug Design Defect Claim
Posted on 3 Dec 2012 by Tom Moylan

WASHINGTON, D.C. - (Mealey's) The U.S. Supreme Court on Nov. 30 said it will review a First Circuit U.S. Court of Appeals ruling that a defective design claim involving a generic drug is not preempted by federal law, placing in jeopardy a $21 million... Read More

Tags: Karen Bartlett , nonsteroidal anti-inflammatory drug , Clinoril , preemption , toxic epidermal necrolysis , Stevens-Johnson syndrome , drug litigation , First Circuit , Mutual Pharmaceutical Company v. Karen L. Bartlett , Litigation , generic drug , defective design claim , U.S. Supreme Court , sulindac , verdict , Mutual Pharmaceutical Co.

Split Supreme Court Says Generic Drug Warning Claims Are Preempted
Posted on 23 Jun 2011 by Tom Moylan

WASHINGTON, D.C. - (Mealey's) State tort law failure-to-warn claims involving the generic drug metoclopramide are preempted by federal law, the U.S. Supreme Court said June 23 in a 5-4 ruling ( Pliva, Inc., et al. v. Gladys Mensing , No. 09-993, Actavis... Read More

Tags: Supreme Court , drugs , preemption , Inc. v. Julie Demahy , Actavis Elizabeth LLC v. Gladys Mensing , Food and Drug Administration , tort law , Actavis Inc. , FDA , Food Drug and Cosmetic Act , failure-to-war , FDCA , Pliva Inc. , Litigation , Actavis Elizabeth LLC , Pliva Inc. v. Gladys Mensing , metoclopramide , generic drug , Hatch-Waxman Amendments , Actavis , Wyeth v. Levine